4.3 Article

Farnesoid X receptor associates with β-catenin and inhibits its activity in hepatocellular carcinoma

Journal

ONCOTARGET
Volume 6, Issue 6, Pages 4226-4238

Publisher

IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.2899

Keywords

Farnesoid X receptor; beta-Catenin; TCF4; Hepatocellular carcinoma

Funding

  1. National Natural Science Foundation of China (NSFC) [81173078, 81100344, 81371268]
  2. National Basic Research Program of China (973 Program) [2010CB912104]

Ask authors/readers for more resources

The association between the temporal activation of Wnt/beta-catenin pathway and the spontaneous hepatocellular carcinoma (HCC) development in Farnesoid X receptor (FXR) knockout mice is not well understood. We found that Huh7 cells depleted with FXR by RNAi showed enhanced cell growth, migration and invasion in vitro and accelerated tumor xenografts formation in nude mice. And these phenotypes were attenuated by simultaneous knockdown of beta-catenin with RNAi. Furthermore, we identified that FXR could bind with beta-Catenin through AF1 domain, and disrupt the assembly of the core beta-Catenin/TCF4 complex. Activation of FXR attenuated the DNA-binding activity of beta-Catenin/TCF4, and subsequently, its targeting gene-cyclin D1 expression. Importantly, FXR expression was markedly reduced in human HCC, an event which correlated with aberrant activation of beta-Catenin. These data identified FXR as a negative regulator of HCC development through direct suppression of Wnt/beta-catenin pathway.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available